SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Care-plan review) — Edward W. Brooke — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientEdward W. Brooke
Date of birth1919-10-26
IdentifiersMRN HR-ML014-SYN-TD; SSN (made up) 000-14-5063
Document date2003-08-11
AuthorHoward Bellamy, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Survivorship visit on tamoxifen. [S]

History of Present Illness

Mr. Brooke returns three months after his last visit, about nine and a half months into tamoxifen and ten months after surgery. He has missed no doses. Hot flashes remain mild; libido is unchanged and he is not troubled by it. He has had no leg swelling or pain, chest pain, breathlessness, or change in vision, and no new lump, skin change, or swelling on either side of the chest or in either armpit, no bone pain, cough, or weight loss. Since his last visit he has begun speaking publicly about breast cancer in men, to encourage men to have a lump or discomfort in the chest checked and to ask their doctors to examine them. He walks most days and feels well. [S]

ElementDetail
TamoxifenAbout nine and a half months; no missed doses
Side effectsMild hot flashes; lower libido, not bothersome
Recurrence symptomsNone
FunctionIndependent; walking most days; busy with speaking and writing

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fatigue, fever, or weight loss
EndocrinePositiveMild hot flashes
CardiovascularNegativeNo chest pain or leg swelling or pain
RespiratoryNegativeNo cough or breathlessness
MusculoskeletalNegativeNo bone pain
PsychiatricNegativeMood good; PHQ-2 score 0

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years)One tablet once dailyOral route2002-10-28activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2003-02-10activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2003-08-11Body height183cmS
2003-08-11Body weight82kgS
2003-08-11Body mass index (BMI) [Ratio]24.5kg/m2S
2003-08-11Systolic blood pressure128mm[Hg]S
2003-08-11Diastolic blood pressure72mm[Hg]S
2003-08-11Heart rate68/minS
2003-08-11Respiratory rate14/minS
2003-08-11Body temperature36.7CelS
2003-08-11Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2003-08-11Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 2003-08-11; see the Vital Signs section. [S]

SystemFinding
GeneralWell
Chest wallMastectomy scars healed on both sides; no nodule or skin change
Lymph nodesNo axillary, supraclavicular, or cervical nodes
AbdomenSoft; liver not enlarged
MusculoskeletalNo spinal tenderness
ExtremitiesArm circumferences equal; no calf swelling or tenderness

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast canceractiveconfirmed C50.121S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D).
Estrogen receptor-positive status of the breast canceractiveconfirmed Z17.0S — Synthetic receptor result; his tumor biology was not made public.
Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health reviewactiveconfirmed Z79.810S — Synthetic adjuvant therapy in the modern episode.
Absence of both breasts after bilateral mastectomyactiveconfirmed Z90.13S — The double mastectomy is reported publicly (D); the coding is synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationCancer-related history and examination of both sides of the chest wall and both axillaeEvery 3 to 6 months for 3 yearsCompleted todayNo evidence of recurrence
ExaminationLymphedema assessmentEvery visit after axillary surgeryCompleted todayNo arm swelling
Medication safetyVenous thromboembolism symptoms on tamoxifenEvery visit on tamoxifenCompleted todayNone
Medication safetyHot flashes on tamoxifenEvery visit on tamoxifenCompleted todayMild
Medication safetySexual side effects of tamoxifenEvery visit on tamoxifenCompleted todayLower libido, stable; no treatment wanted
Medication safetyAdherence to tamoxifenEvery visit on tamoxifenCompleted todayNo missed doses
SurveyDistress and depression screen (PHQ-2)Every visitCompleted todayPHQ-2 score 0
SurveyFatigue and cognitive concernsEvery visitCompleted todayNone
ImagingBone density (DXA)Every 2 years on hormone therapyUp to dateSix months ago; next in eighteen months
ImagingBreast imaging (mammography)Yearly only for a remaining breast after lumpectomy, or the other breast with a predisposing variantNot indicatedBoth breasts were removed; there is no breast tissue to image
LaboratoryRoutine blood tests, tumor markers, and CT, bone scan, or PETNot recommended without symptoms in stage I to III diseaseNot indicatedNo symptoms suggesting recurrence
Self-managementSurvivorship care plan and lifestyle counselingWithin a year of treatment; lifestyle every visitCompleted todayWritten plan given; at least 150 minutes of activity a week; no tobacco or alcohol

Goal progress:

Guideline basis: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)

Follow-up: Annual wellness visit in two months. Survivorship visit in three to six months. Medical oncology every six months. Next scheduled visit 2003-10-13: subsequent annual wellness visit. [S]